Icade SA (ICAD)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 14.58 |
|---|---|
| 52-week range | 14.21 – 22.76 |
| Return, 1 month / 3 months | −11.9% / −23.8% |
| Return, 1 year / 3 years | −26.4% / −16.2% |
| Trend | Below its 200-day average |
| RSI (14) | 32 |
| Volatility (1 year) | 22.1% |
| Worst drawdown (1 year) | -29.6% |
| Average daily value traded | 1.86M EUR |
| Dividend yield | 13.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Icade is a French real estate company based in France that combines property investment with property development. It owns and manages a portfolio of offices, business parks and healthcare facilities, serving corporate tenants and public-sector occupiers. Through its development business, Icade builds homes, offices and other projects, and it also provides property management and related services to institutional and individual clients.
Icade SA trades under the code ICAD on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Icade SA (ICAD) trades on the Euronext Paris in France. It last closed at EUR 14.58 on 23 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 292 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 26.4% and over the last three months it fell 23.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 33 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.9% | ||
| From 52-week high | -35.5% | ||
| Momentum | 27 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -23.8% | ||
| 6-month return | -22.2% | ||
| 12-month return, skipping the last month | -16.4% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.6% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 1.86M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 78 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 13.2% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −1.4% |
|---|---|
| 1 month | −11.9% |
| 3 months | −23.8% |
| 6 months | −22.2% |
| 1 year | −26.4% |
| 3 years | −16.2% |
| 5 years | −58.1% |
Signals
| 50-day / 200-day average | 16.60 / 18.21 |
|---|---|
| Golden / death cross (60 days) | Death, 30 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.38 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Jun 2026 | EUR 1.9200 |
| 1 Jul 2025 | EUR 2.1500 |
| 4 Mar 2025 | EUR 2.1600 |
| 2 Jul 2024 | EUR 2.4200 |
| 4 Mar 2024 | EUR 2.4200 |
| 4 Jul 2023 | EUR 2.1700 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.